Finance

Traders Watch list: Banco Santander Brasil SA (NYSE:BSBR) & Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE)

Banco Santander Brasil SA (NYSE:BSBR)

Banco Santander, S.A. is a retail and commercial bank. The Banks segments include Continental Europe, the United Kingdom, Latin America and the United States. The Continental Europe segment covers all businesses in the Continental Europe. The United Kingdom segment includes the businesses developed by various units and branches in the country. The Latin America segment embraces all its financial activities conducted through its banks and subsidiaries in the region. The United States segment includes the Intermediate Holding Company (IHC) and its subsidiaries Santander Bank, Banco Santander Puerto Rico, Santander Consumer USA, Banco Santander International, Santander Investment Securities, and the Santander branch in New York. The Company’s commercial model satisfies the needs of all types of customers: individuals with various income levels.

Banco Santander Brasil SA (NYSE:BSBR)’s Financial Overview

Banco Santander Brasil SA (NYSE) surged 0.23% yesterday to close its trading session at $13.2. The company has 1 year Price Target of $10.58. Banco Santander Brasil SA has 52-Week high of $13.5 and 52-Week Low of $7.2. The stock touched its 52-Week High on 13.43 and 52-Week Low on 7.06. The stock traded with the volume of 769867 shares yesterday. The firm shows the market capitalization of $48.95 Billion.

Banco Santander Brasil SA (NYSE) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $0.21/share against the analyst consensus estimate of $0.22/share. The difference between the actual and expected EPS is $-0.01 a share with a surprise factor of -4.5%.

The firm is trading with SMA20 of 5.18 Percent, SMA50 of 14.16 Percent and SMA200 of 34.23 percent. Banco Santander Brasil SA has P/S value of 2.63 while its P/B value stands at 2.05. Similarly, the company has Return on Assets of 1.7 percent, Return on Equity of 12.8 percent and Return on Investment of 10.4 Percent. The company shows Gross Margin and Operating Margin of 0 percent and 52.6 percent respectively.

The Stock currently has Analyst’ mean Recommendation of 3.3 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 10 analysts offering 12-month price forecasts for Banco Santander Brasil SA have a median target of 11.10, with a high estimate of 13.46 and a low estimate of 8.45. The median estimate represents a -15.91% decrease from the last price of 13.20.

Banco Santander Brasil SA is expected* to report earnings on 01/30/2019 before market open. The report will be for the fiscal Quarter ending Dec 2018. According to Zacks Investment Research, based on 2 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.23. The reported EPS for the same quarter last year was $0.2.

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE)

Aeglea BioTherapeutics, Inc. is a biotechnology company which is engaged in developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. Its portfolio of products consists of AEB1102, AEB3103, AEB2109 and AEB4104 which are in different clinical trial phase. Aeglea BioTherapeutics, Inc. is based in Austin, Texas.

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE)’s Financial Outlook

The 6 analysts offering 12-month price forecasts for Aeglea Bio Therapeutics Inc have a median target of 17.50, with a high estimate of 33.00 and a low estimate of 10.00. The median estimate represents a +101.15% increase from the last price of 8.70.

Aeglea BioTherapeutics, Inc. is estimated to report earnings on 03/12/2019. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.37. The reported EPS for the same quarter last year was $-0.38.

According to Zacks Investment Research, Aeglea BioTherapeutics, Inc. has a Consensus Recommendation of 1.75. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock surged 2.23% and closed its last trading session at $8.7. The company has the market capitalization of $203.41 Million. The stock has 52-week high of $12 and 52-Week low of $5.12. The firm touched its 52-Week high on 12.00 and 52-Week low on 5.12. The company has volume of 40639 shares. The company has a total of 23.38 Million shares outstanding.

Aeglea BioTherapeutics, Inc. (NASDAQ) in the last quarter reported its actual EPS of $-0.54/share where the analyst estimated EPS was $-0.45/share. The difference between the actual and Estimated EPS is $-0.09. This shows a surprise factor of -20 percent.

The company has YTD performance of 16.15 percent. Beta for Aeglea BioTherapeutics, Inc. stands at 0 while its ATR (average true range) is 0.49. The company has Weekly Volatility of 4.82%% and Monthly Volatility of 5.76%%.

Aeglea BioTherapeutics, Inc. has distance from 20-day Simple Moving Average (SMA20) of 3.16%, Distance from 50-Day Simple Moving Average of 7.91 percent and Distance from 200-Day Simple Moving Average of -5.02%.

The Company currently has ROA (Return on Assets) of -56 percent, Return on Equity (ROE) of -62.1 Percent and Return on Investment (ROI) of -55% with Gross margin of 0 percent and Operating & Profit margin of 0% and 0% respectively.